THE GLOBAL CRISIS OF DEPRESSION - Lundbeck depression... · the global crisis of depression ... the burden of depression ... 16.50 panel discussion: facing down depression; engendering
This document is posted to help you gain knowledge. Please leave a comment to let me know what you think about it! Share it to your friends and learn new things together.
The Economist EventsThe Economist Events is a part of The Economist Group, publisher of The Economist newspaper. Sharing The Economist’s commitment to informed, impartial and independent debate, we are recognised the world over as a leading provider of highly interactive meetings—including industry conferences, private gatherings and government roundtables—for senior executives seeking new insights into important strategic issues.
THE GLOBAL CRISIS OF DEPRESSIONTHE LOW OF THE 21ST CENTURY?
TUESDAY, NOVEMBER 25TH 2014 KINGS PLACE, LONDON
O F F I C I A L P R A G E N C Y :
www.depression.economist.com
www.depression.economist.com
WEL
COM
E
MEDIA PACK
THE GLOBAL CRISIS OF DEPRESSIONTHE LOW OF THE 21ST CENTURY?
November 25th 2014
PRESS REGISTRATION Registration starts at: 08:15. There will be a separate desk located in the registration area clearly marked: ‘PRESS’. Please bring your business/press card with you and valid ID. For security reasons if somebody else will be attending in your place please let us know prior to the event. Only accredited press will be allowed to attend the summit.
WI-FI AND INTERNET ACCESS This is free for all conference attendees. Please use the following wifi login details:
Username: mentalhealth Password: november
A dedicated press room is available where you can charge your laptop/ tablet if needed.
SOCIAL MEDIA We will be tweeting live from the event. If you are a Twitter user we encourage you to tweet using the following hashtag: #depressionsummit. You can also follow us on @EconomistEvents.
LUNCH AND REFRESHMENTS Refreshments will be served in the press room. Press are invited to attend lunch together with delegates and there will be tables reserved for press.
ACCESS TO SESSIONS Press are invited to attend all sessions. An area in the back of the conference room will be clearly marked for press. Any photos taken inside conference room should be taken before the session starts.
There will be a designated area to conduct any speaker interviews and take photos after the session.
CONTACTS For further information, please contact Edelman at [email protected] or tel: 0203 047 2343.
A STRONG ECONOMIC AND SOCIAL CASE FOR PREVENTING, CONTROLLING AND MANAGING DEPRESSION
09.10 SPECIAL ADDRESS: THE BURDEN OF DEPRESSION
Kofi Annan, Former Secretary General, United Nations; Chairman, Kofi Annan Foundation
09.50 KEYNOTE ADDRESS: THE POLITICAL IMPERATIVES TO ADDRESS MENTAL HEALTH AND DEPRESSION
RT Hon Norman Lamb MP, Minister of State for Care and Support, Department of Health, United Kingdom
10.20 NETWORKING AND REFRESHMENT BREAK
FIGHTING DEPRESSION – THE CASE FOR PREVENTION AND HEALTH PROMOTION IN DEPRESSION
10.50 OPENING KEYNOTE
Nick Hækkerup, Minister of Health, Denmark
11.10 CARRYING THE WEIGHT: THE BURDEN OF DEPRESSION AND KEY TRENDS FOR THE FUTURE, INCLUDING THE ECONOMIC COSTS OF THE ILLNESS
Hans-Ulrich Wittchen, Chairman and Director, Institute of Clinical Psychology and Psychotherapy; Center of Clinical Epidemiology and Longitudinal Studies (CELOS), Dresden Technical University
11.30 INTERVIEW: UNDERSTANDING THE COMPLEXITY OF DEPRESSION AND OF TREATING DEPRESSION
Simon Wessely, Professor of Psychological Medicine at the Institute of Psychiatry, King’s College
11.55 FINDING A KEY TO BEATING DEPRESSION: A PERSONAL STORY
David Kinder, Deputy Director, Workforce, Pay and Pensions, Public Spending Group, HM Treasury
12.15 NETWORKING LUNCH
FIGHTING BACK – HOW SHOULD DEPRESSION ACROSS ALL STRATA OF SOCIETY BE TREATED IN THE 21ST CENTURY?
13.15 OPENING PANEL DISCUSSION: FUTURE TOOLS FOR PATIENT TREATMENT
This opening panel discussion will feature three stakeholders representing the NHS, the
physician and the manufacturer. It has been over a decade since a new antidepressant has
been launched. Psychiatric and CNS research has largely been curtailed in Europe due to the
risk involved in this therapeutic area. Where will better treatment or even a cure come from?
How should policy makers, society and the industry work together to incentivise and develop
a step change in treatment? What role do financial incentives have in the future of
developing cures for depression? What is the future for non-pharmacological treatments?
How important is primary care?
David Haslam CBE, Chair, NICE (National Institute for Health and Care Excellence)
David Nutt, Professor of Neuropsychopharmacology, Imperial College, UK; President, European Brain Counci (EBC)
Depression is a complex problem, with different patients requiring different treatments. This
high-level panel will look at what we can and should do as depression becomes an even
greater issue in Europe, with discussions on the role of prevention, health promotion, talking
therapies and medical solutions, and how to fill existing treatment gaps.
Mary G Baker, Immediate Past-president, European Brain Council (EBC)
George N Christodoulou, Professor of Psychiatry and Chairman of the Department of Psychiatry, University of Athens, Greece; President, World Federation of Mental Health (WFMH)
Christopher Dowrick, Professor of Primary Medical Care, University of Liverpool
Ulrich Hegerl, President, European Alliance against Depression; Chair and Medical Director of the Department of Psychiatry, Leipzing University
Moderated by: Linda Rosenberg, President and Chief Executive Officer, National Council for Behavioral Health, USA
14.45 NETWORKING AND REFRESHMENT BREAK
THE CHALLENGE OF DEPRESSION IN THE WORKPLACE
15.15 AN EMPLOYER’S PERSPECTIVE
Lord Dennis Stevenson, former Chair, HBOS, Trustee, MQ: Transforming Mental Health
Depression is the biggest mental health challenge among people of working-age, and the leading
cause of disability worldwidei.
More than 30 million people in Europe are affected by depression, most of whom are working ageii.
On a global level, depression, the leading cause of disability worldwideiii, affects 350 million peopleiv.
Depression has significant socio-economic costs. The costs of depression in the EU were estimated at
€92 billion in 2010, with the majority (€54 billion) being indirect such as lost work productivity due
to, for example, sick leave and early retirementv.
The cognitive symptoms of depression - concentration difficulties, indecisiveness, and/or
forgetfulness - are present up to 94% of the time in an episode of depression and cause significant
impairment in work functionvi. People with depression report on average 5.6 hours per week of total
health-related lost productivity time (LPT) more than those without depression - eighty-one percent
of those LPT costs are explained by reduced performance while at work, i.e. presenteeismvii.
1 in 10 workers has taken time off work due to depression, with 36 working days lost per depressive
episode. Yet, in spite of this, one in three managers say they do not have formal support or resources
to deal with the problemviii.
According to a recent report by the London School of Economics and Political Science and King’s
College London, the cost of depression to European businesses is estimated at £77 billion per year,
with the greatest loss attributed to absenteeism (frequent absence from work) and lost
productivityix.
More than half of patients do not achieve adequate response following first antidepressant
treatment and remission rates are progressively lower for each successive treatment step, which
highlight the need to provide effective therapies early in depression treatmentx.
According to the OECD’s recent report on mental health, there is an extremely large treatment gap
within depression, with a median 56.3%xi. As result, the OECD recommends that governments
strengthen and scale-up treatment for depression.
Studies show that the costs of treating depression are outweighed by productivity benefits in terms
of reduced rates of absenteeism and presenteeism (attending work whilst unwell)xii. For example,
data from the UK show that every Pound invested in early diagnosis and treatment of depression at
work will yield a cross-sector return of £5xiii.
But the benefits extend beyond employer bottom lines. The early identification and optimum
management of depression and its cognitive symptoms (trouble concentrating, indecisiveness,
forgetfulness) will help people with depression receive appropriate treatment to facilitate recovery
and return to work, bringing benefits from a social, family and economic perspectivexiv.
The longer depression goes untreated, the more debilitating the condition becomes, which in turn
leads to even greater strain on national disability funds .
Research has shown that people experiencing major depression have an 11% decline in work
productivity due to increased confusion, inattention, memory issues, apathy and sleep dysfunction .
i World Health Organisation. Depression Factsheet. Available at: http://www.who.int/mediacentre/factsheets/fs369/en/
ii Evans-Lacko S, Knapp M. Importance of Social and Cultural Factors for Attitudes, Disclosure and Time off Work for Depression: Findings from a Seven Country European Study on Depression in the Workplace. PLOS One. DOI: 10.1371/journal.pone.0091053
iii World Health Organisation. Depression Factsheet. Available at: http://www.who.int/mediacentre/factsheets/fs369/en/
iv European Pact for Mental Health and Well-being, 2008; J. Olesen, et al. Eur J Neurology. 2012;19:155–162
v J. Olesen, et al. Eur J Neurology. 2012;19:155–162
vi J. Olesen, et al. Eur J Neurology. 2012;19:155–162
vii Stewart WF, et al. JAMA, 2003;289(23):3135–3144
viii European Depression Association (EDA), Impact of Depression in Europe Audit Survey (IDEA Survey), 2012
ix Evans-Lacko S, Knapp M. Importance of Social and Cultural Factors for Attitudes, Disclosure and Time off Work for Depression: Findings from a Seven Country European Study on Depression in the Workplace. PLOS One. DOI: 10.1371/journal.pone.0091053
x Rush AJ et al. Am J Psychiatry 2006 Nov;163(11):1905-17.
xi OECD, 2014, Making Mental Health Count
xii Kessler RC et al. Depression in the workplace: effects on short-term disability. Health Affairs. September 1999 vol. 18 no. 5 163–171; Simon GE et al. Depression and Work Productivity: The Comparative Costs of Treatment Versus Nontreatment. Journal of Occupational & Environmental Medicine. January 2001;43(1):2–9; Knapp M et al. Mental Health Promotion and Prevention: The Economic Case. January 2011. https://www.gov.uk/government/uploads/system/uploads/attachment_data/file/215626/dh_126386.pdf
xiii European Commission report 2011. Mental well-being: For a smart, inclusive and sustainable Europe. http://ec.europa.eu/health/mental_health/docs/outcomes_pact_en.pdf
xiv Naismith SL et al. Disability in major depression related to self-rated and objectively-measured cognitive deficits: a preliminary study. BMC Psychiatry 2007: 7:32; Zhang M et al. A Community Study of Depression Treatment and Employment Earnings. Psychiatric Services. September 1999.
xv Sick on the job? Myths and Realities about Mental Health and Work. OECD, 2012.
xvi Stephens T et al. The Economic Burden of Mental Health Problems in Canada. Chronic Dis Can. 2001;22(1):18–23; Lerner D et al. The clinical and occupational correlates of work productivity loss among employed patients with depression. J Occup Environ Med. 2004 Jun;46(6 Suppl):S46–55.
Factsheet from our sponsor:
@EconomistEvents #depressionsummit
SPO
NSO
R PR
OFI
LE
H. Lundbeck A/S is a global pharmaceutical company specialized in brain diseases. For more than 50
years, we have been at the forefront of research within neuroscience. Our key areas of focus are alcohol
Parkinson’s disease, schizophrenia, stroke and symptomatic neurogenic orthostatic hypotension
(NOH).
An estimated 700 million people worldwide are living with brain disease and far too many suffer due to
inadequate treatment, discrimination, a reduced number of working days, early retirement and other
unnecessary consequences. Every day,we strive for improved treatment and a better life for people
living with brain disease – we call this Progress in Mind.
Read more at www.lundbeck.com/global/about-us/progress-in-mind.
Our approximately 6,000 employees in 57 countries are engaged in the entire value chain throughout
research, development, production, marketing and sales. We have research centres in China, Denmark
and the United States and production facilities in China, Denmark, France and Italy.
For additional information, we encourage you to visit our corporate site www.lundbeck.com
More than 700 million people are affected by brain disease worldwide - this is equal to 13% of the global disease burden.1
Prevalent disorders such as depression, dementia and addiction account for 35% of Europe’s total disease burden.2,3,4
The European Brain Council estimates that the cost of brain diseases is € 798 billion in Europe alone.2,3,4
All over the world, brain disease is a growing burden, not only for individuals but for families and societies as well.
An estimated 700 million people worldwide are living with brain disease and far too many suffer due to inadequate treatment, discrimination, a reduced number of working days, early retirement and other unnecessary consequences.
Lundbeck is a specialized pharmaceutical company focusing on brain disease. For more than 50 years, we have been at the forefront of research within neuroscience and our development and distribution of pioneering treatments continues to
make a difference to people living with brain disease.
We are recognized for having helped hundreds of millions of people suffering from brain disease, such as depression, alcohol dependence, schizophrenia, epilepsy, and Alzheimer’s, Parkinson’s and Huntington’s disease. However, there is still a massive need for help.
Every day, we strive for improved treatment and a better life for people living with brain disease – we call this Progress in Mind.
www.lundbeck.com/global/about-us/progress-in-mind
Facts about brain disease
1. www.ifpma.org/fileadmin/content/Global%20Health/Mental_Health/2012_IFPMA_Position_Paper_on_MNDs.pdf2. Gustavsson et al. –Cost of disorders of the brain in Europe 2010. 3. European Neuropharmacalogy, 2011.& Wittchen, H.U. et al. – The size and burden of mental disorders and other disorders of the brain in Europe, 2011. 4. WHO Mental Health Atlas 2011
Why do almost 50% of people with brain diseases not receive any treatment?
www.depression.economist.com
Abu Dhabi, Ahmedabad, Amsterdam, Atlanta, Austin, Bangalore, Barcelona, Beijing, Berlin, Brussels, Buenos Aires, Calgary, Chennai, Chicago, Dallas, Dubai, Dublin, Frankfurt, Guangzhou, Hamburg, Ho Chi Minh City, Hong Kong, Houston, Hyderabad, Istanbul, Jakarta, Johannesburg, Kolkata, Kuala Lumpur, London, Los Angeles, Madrid, Melbourne, Mexico City, Miami, Milan, Montreal, Moscow, Mumbai, Munich, New Delhi, New York, Orlando, Paris, Pegasus Beijing, Pegasus Shanghai, Portland, Pune, Rio de Janeiro, Rome, Sacramento, San Francisco, São Paulo,
Seattle, Seoul, Shanghai, Silicon Valley, Singapore, Stockholm, Sydney, Taipei, Tokyo, Toronto, Vancouver, Warsaw, Washington, D.C., Zurich
INDEPENDENCEWith over 5,000 people in 65 countries around the world, we’ve become the industry leader by focusing on
what’s best for our clients and giving our talent the freedom to flourish. Put our independence to work for you.
SHOW UP DIFFERENTLY
#ShowUpDifferently Learn more at www.Edelman.com
Edelman Independence A4 Ad Nov 2014.indd 12 05/11/2014 18:59